Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | OXTR | P30559 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12407348 | 0.94 | PTGER1 (0.62) | PTGER1NPSR1THRBOXTR | |
| SCHEMBL12407340 | 0.94 | TP53 (0.62) | PTGER1KMT2ATHRB | |
| SCHEMBL12407359 | 0.92 | PTGER1 (0.60) | PTGER1NPSR1THRBOXTR | |
| SCHEMBL12407349 | 0.92 | PTGER1 (0.77) | PTGER1NPSR1KMT2ATHRBOXTR | |
| SCHEMBL12407392 | 0.90 | PTGER1 (0.58) | PTGER1NPSR1THRBOXTR | |
| SCHEMBL12407163 | 0.90 | PTGER1 (0.78) | PTGER1KMT2A | |
| SCHEMBL12407196 | 0.90 | THRB (0.67) | PTGER1LMNAKMT2ATHRBOXTR | |
| SCHEMBL12407373 | 0.90 | PTGER1 (0.57) | PTGER1NPSR1LMNAKMT2ATHRB | |
| SCHEMBL12407344 | 0.89 | PTGER1 (0.68) | PTGER1LMNATHRB | |
| SCHEMBL12407641 | 0.87 | PTGER1 (0.58) | PTGER1LMNAKMT2ATHRBOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | PTGER1 1/4885NPSR1 32/4885LMNA 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.